Section Arrow
MIRM.NASDAQ
- Mirum Pharmaceuticals
Quotes are at least 15-min delayed:2026/04/15 22:31 EDT
Regular Hours
Last
 96.4
-0.5 (-0.52%)
Day High 
97.37 
Prev. Close
96.9 
1-M High
99.4069 
Volume 
470.73K 
Bid
94.5
Ask
100.01
Day Low
94.94 
Open
96.9 
1-M Low
84.94 
Market Cap 
5.85B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 95.86 
20-SMA 92.93 
50-SMA 95.83 
52-W High 109.28 
52-W Low 38.22 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.47/-0.33
Enterprise Value
6.16B
Balance Sheet
Book Value Per Share
5.22
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
521.31M
Operating Revenue Per Share
2.40
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.544+0.2292+72.81%-- 
LIMNLiminatus Pharma Inc0.1856+0.0058+3.23%-- 
PPCBPropanc Biopharma Inc0.1106+0.0131+13.44%0PE
ALLOAllogene Therapeutics2.17-0.11-4.82%-- 
CUECue Biopharma0.7243+0.2863+65.37%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.